## Part I  Clinical Aspects

1 **History of the Israeli Cohort of Laron Syndrome Patients (1958–2009)**
   Zvi Laron ................................................. 3

2 **Early Investigations: Characterizations of the Circulating Growth Hormone**
   Zvi Laron ................................................. 9

3 **Clinical Evidence of Growth Hormone Resistance in Patients with Laron Syndrome**
   Zvi Laron ................................................. 21

4 **Diagnosis of Laron Syndrome**
   Zvi Laron ................................................. 27

5 **Genetic Aspects**
   Orit Shevah and Zvi Laron ................. 29
   5.1 **Genetic Investigations**
      Orit Shevah and Zvi Laron .................. 29
   5.2 **Hypothesis of the Origin of Laron Syndrome**
      Zvi Laron and Orit Shevah .................. 47
   5.3 **Are the Pygmies Laron Syndrome Patients?**
      Zvi Laron ............................................. 50

6 **Clinical Evaluation**
   Zvi Laron ................................................. 53

7 **Perinatal Development in Laron Syndrome**
   Zvi Laron and Rivka Kauli .................... 59

8 **Linear Growth Pattern of Untreated Laron Syndrome Patients**
   Zvi Laron and Rivka Kauli .................... 63
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>9</td>
<td>Head Shape, Size, and Growth of Untreated Patients with Laron Syndrome</td>
<td>91</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron and Rivka Kauli</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>Sexual Development in Patients with Laron Syndrome</td>
<td>101</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron and Rivka Kauli</td>
<td></td>
</tr>
<tr>
<td>11</td>
<td>Sex Hormone Binding Proteins and Sex Hormones in Untreated and IGF-I Treated Patients with Laron Syndrome</td>
<td>119</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron and Rivka Kauli</td>
<td></td>
</tr>
<tr>
<td>11.1</td>
<td>Sex Hormone Binding Proteins</td>
<td>119</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>11.2</td>
<td>Sex Hormones in Untreated Patients with Laron Syndrome</td>
<td>121</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron and Rivka Kauli</td>
<td></td>
</tr>
<tr>
<td>12</td>
<td>The Adipose Tissue in Patients with Laron Syndrome</td>
<td>125</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>13</td>
<td>Investigations to Determine the Cause of Obesity in Patients with Laron Syndrome</td>
<td>135</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron, Shira Ginsberg, and Nahum Vaisman</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>Nonalcoholic Fatty Liver Disease (NAFLD) in Patients with Laron Syndrome</td>
<td>143</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>15</td>
<td>Serum Lipids in Patients with Laron Syndrome</td>
<td>149</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>16</td>
<td>Adiponectin and Leptin in Laron Syndrome</td>
<td>157</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron and Hannah Kanety</td>
<td></td>
</tr>
<tr>
<td>17</td>
<td>Muscle Force and Endurance in Untreated Adult and IGF-I Treated Children with Laron Syndrome</td>
<td>161</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>18</td>
<td>Bone Mineral Density in Untreated and IGF-I or Alendronate-Treated Patients with Laron Syndrome</td>
<td>165</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>19</td>
<td>Muscle–Bone Relationship in Patients with Laron Syndrome</td>
<td>171</td>
</tr>
<tr>
<td></td>
<td>Yoram Epstein, Amir Hadid, Zvi Laron, Daniel S. Moran, and Nahum Vaisman</td>
<td></td>
</tr>
<tr>
<td>19.1</td>
<td>Bone Characteristics</td>
<td>171</td>
</tr>
<tr>
<td></td>
<td>Yoram Epstein, Amir Hadid, Zvi Laron, and Daniel S. Moran</td>
<td></td>
</tr>
<tr>
<td>19.2</td>
<td>Lean Body Mass (LBM) in Patients with Laron Syndrome</td>
<td>173</td>
</tr>
<tr>
<td></td>
<td>Zvi Laron and Nahum Vaisman</td>
<td></td>
</tr>
</tbody>
</table>
20 Imaging Findings in Laron Syndrome ............................................. 175
Liora Kornreich and Zvi Laron

21 Ocular Findings in Laron Syndrome ............................................. 201
Dan H. Bourla and Dov Weinberger

22 Hearing in Patients with Laron Syndrome ................................. 209
Zvi Laron, Omer Zarchi, and Joseph Attias

23 The Teeth in Patients with Laron Syndrome ............................. 213
Zvi Laron

24 Hair, Skin, and Nails in Patients with Laron Syndrome .......... 219
Zvi Laron

25 Hand, Foot, and Organ Size and Growth in Untreated and IGF-I Treated
Patients with Laron Syndrome .................................................. 227
Zvi Laron and Aviva Silbergeld

25.1 Hand Size and Growth of Untreated and IGF-I Treated
Laron Syndrome Patients ....................................................... 227
Zvi Laron

25.2 Foot Size and Growth in Untreated and IGF-I-Treated
Patients with Laron Syndrome .................................................. 231
Zvi Laron and Aviva Silbergeld

25.3 Organ Size ................................................................. 233
Zvi Laron

26 Lifelong Serum Growth Hormone Levels in
Patients with Laron Syndrome .................................................. 235
Zvi Laron and Orly Efros

27 IGF-I Binding Proteins in Laron Syndrome ......................... 241
Zvi Laron

28 Serum Prolactin in Untreated and IGF-I Treated
Patients with Laron Syndrome .................................................. 247
Zvi Laron and Orly Efros

29 Thyroid Hormones in Untreated and IGF-I
Treated Patients with Laron Syndrome ...................................... 255
Zvi Laron and Rivka Kauli

30 Insulin Secretion and Carbohydrate Metabolism in
Patients with Laron Syndrome: From Hypoglycemia
to Diabetes Mellitus ............................................................. 259
Zvi Laron

31 Liver Enzymes in Patients with Laron Syndrome ................. 273
Zvi Laron and Tsvia Karmon
32  The Hematopoietic System in Patients with Laron Syndrome ....... 283
    Zvi Laron

33  Cardiovascular Aspects in Laron Syndrome Patients ............... 293
    Mickey Scheinowitz, Micha S. Feinberg, Michael Shechter,
    Zvi Laron, and Rivka Kauli

33.1 Heart Functions in Untreated and IGF-I-Treated
    Patients with Laron Syndrome ................................. 293
    Mickey Scheinowitz, Micha S. Feinberg, and Zvi Laron

33.2 Endothelial Function in Adults with Laron Syndrome
    (Primary Growth Hormone Insensitivity) ..................... 298
    Michael Shechter and Zvi Laron

33.3 Intimal Thickness of the Extracranial Arteries in
    Untreated Adult Patients with Laron Syndrome ............... 300
    Zvi Laron

33.4 Cardiovascular Disease ...................................... 303
    Zvi Laron and Rivka Kauli

34  Kidney Functions in Untreated and IGF-I
    Treated Patients with Laron Syndrome ......................... 307
    Zvi Laron

35  Sleep and Sleep Disorders in Patients with Laron Syndrome ....... 317
    Zvi Laron, Rivka Kauli, and Eyal Rosenzweig

35.1 Sleep Quality ............................................. 317
    Zvi Laron and Rivka Kauli

35.2 Severe Obstructive Sleep Apnea (OSA) ........................ 318
    Zvi Laron

35.3 Additional Polysomnographic Examinations
    of Patients with Laron Syndrome ............................... 318
    Eyal Rosenzweig and Zvi Laron

36  Neurological Aspects in Laron Syndrome ........................ 321
    Zvi Laron

37  Orthopedic Problems in Laron Syndrome ........................ 323
    Zvi Laron and Rivka Kauli

38  Psychological Aspects in Patients with Laron Syndrome .......... 325
    Zvi Laron

39  Adjustment and Rehabilitation Problems of
    Children, Adolescents, and Adults with Laron Syndrome ....... 335
    Zvi Laron

40  Laron Syndrome Patients with Congenital IGF-I
    Deficiency Seem Protected from Malignant Diseases .......... 339
    Zvi Laron, Rachel Steuerman, and Orit Shevah
41 Lifespan and Mortality of Patients with Laron Syndrome ......................................... 341
Zvi Laron

42 IGF-I Treatment of Patients with Laron Syndrome .................................................... 343
Zvi Laron

43 IGF-I Stimulation of Head Growth in Patients with Laron Syndrome .............................. 381
Zvi Laron

44 Effects of Long-Term Administration of IGF-I on the Adipose Tissue and Carbohydrate Metabolism in Children with Laron Syndrome .............................. 389
Zvi Laron

45 Comparison of the Growth Promoting Response of IGF-I in Children with Laron Syndrome with that of hGH in Children with Isolated GH Deficiency ............................ 409
Zvi Laron

46 IGF-I Treatment of Adult Patients with Laron Syndrome ........................................ 413
Zvi Laron

47 Adverse Effects Encountered During IGF-I Treatment of Patients with Laron Syndrome ......................................................... 419
Zvi Laron

48 Summary of the Clinical History: The Laron Syndrome Clock ........................................ 425
Zvi Laron

Part II  The Growth Hormone Receptor “Null” Mouse or the Laron Mouse

49 The Laron Mouse .......................................................... 429
John J. Kopchick and John D. Blischak

50 Role of GH/IGF-I Deficiency in Aging ................................................................. 433
Edward O. List

51 Body Composition, Adipose Tissue, and Energy Balance ......................................... 441
Darlene E. Berryman

52 Metabolism and Metabolic Regulation ................................................................. 451
Lucila Sackmann-Sala, D. R. Bailey Miles, and John J. Kopchick

53 Skeletal Muscle ................................................................. 465
Juan Ding and John J. Kopchick
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Title</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>54</td>
<td>Cardiac Function in GHR−/− Mice</td>
<td>473</td>
</tr>
<tr>
<td></td>
<td>Diana Cruz-Topete and John J. Kopchick</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>Bone</td>
<td>481</td>
</tr>
<tr>
<td></td>
<td>Shigeru Okada and Jacob Wright-Piekarski</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td>GHR Knockout and the CNS</td>
<td>489</td>
</tr>
<tr>
<td></td>
<td>Elahu S. Gosney and John J. Kopchick</td>
<td></td>
</tr>
<tr>
<td>57</td>
<td>Cancer</td>
<td>495</td>
</tr>
<tr>
<td></td>
<td>Brian D. Bower and John J. Kopchick</td>
<td></td>
</tr>
<tr>
<td>58</td>
<td>Reproduction</td>
<td>507</td>
</tr>
<tr>
<td></td>
<td>Bruce Kelder</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td>Conclusions and Future Studies</td>
<td>513</td>
</tr>
<tr>
<td></td>
<td>John J. Kopchick, Hiroyoshi Tanda, Darlene Berryman, and Zvi Laron</td>
<td></td>
</tr>
<tr>
<td>Appendix</td>
<td></td>
<td>521</td>
</tr>
<tr>
<td>Index</td>
<td></td>
<td>525</td>
</tr>
</tbody>
</table>
Laron Syndrome - From Man to Mouse
Lessons from Clinical and Experimental Experience
Laron, Z.; Kopchick, J. (Eds.)
2011, XIV, 531 p., Hardcover
ISBN: 978-3-642-11182-2